Advertisement

Thoracic Oncology

Make CHEST Physician® a trusted source
  • Selpercatinib improves event-free survival in early-stage RET fusion-positive NSCLC

    Selpercatinib improves event-free survival in early-stage RET fusion-positive NSCLC

    Alexander E. Drilon, MD, discusses the findings from the first randomized phase 3 trial to evaluate a RET kinase inhibitor as adjuvant therapy in RET fusion-positive lung cancer.


  • Varenicline sampling with minimal guidance may boost smoking cessation rates

    Varenicline sampling with minimal guidance may boost smoking cessation rates

    According to the investigators, the medication sampling model may lower barriers to engagement and allow patients to consider cessation on their own terms.


  • Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases

    Study evaluates amivantamab plus lazertinib for EGFR-mutant NSCLC with CNS metastases

    With the combination now available, Mark Jeng, MD, PhD, revisits positive results from a recent study evaluating the strategy in this high-risk population.



  • Using gastric POCUS in the ICU for aspiration risk assessment

    Using gastric POCUS in the ICU for aspiration risk assessment

    In an era of increasing GLP-1 receptor agonist use and frequent emergency airway interventions, gastric POCUS provides clinically actionable information that fasting history alone cannot.


  • Subsolid pulmonary nodules: From guidelines to real-world practice

    Subsolid pulmonary nodules: From guidelines to real-world practice

    The heterogeneity of guidelines on subsolid pulmonary nodules is likely a contributing factor to the discrepancy between published recommendations and real-world practice, but most societies still prioritize nodule size, development of solid component, and change over time.


  • Putting radon on your clinical radar

    Putting radon on your clinical radar

    Hear from Clifford Mitchell, MD, MPH, Director of the Environmental Health Bureau at the Maryland Department of Health, about when to test, who is most at risk, and why clinicians should make radon awareness part of routine care.


  • First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC

    First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC

    Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.


  • How social determinants of health impact lung cancer care

    How social determinants of health impact lung cancer care

    Patient outcomes in lung cancer care vary greatly by race, geography, income, and access to care. Learn how experts are addressing disparities through education, screening, and culturally responsive and personalized care.



  • Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC

    Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC

    Coauthor Anup Kasi, MD, MPH, said the study represents an important step forward in the development of KRAS G12D-targeted therapies.


  • Seeing the target, missing the risk? Radiation safety in advanced bronchoscopy

    Seeing the target, missing the risk? Radiation safety in advanced bronchoscopy

    While patient exposure receives most of the attention when it comes to radiation risk, careful consideration must be given to the proceduralists and staff who are in the room day after day.


  • The evolution of interventional pulmonology

    The evolution of interventional pulmonology

    Interventional pulmonology has rapidly evolved into a technology-driven specialty, with advances like robotic bronchoscopy and real-time imaging enabling safer, more precise access to peripheral lung lesions. These innovations allow clinicians to combine diagnostic and therapeutic procedures in a single setting.


  • Link between viral pneumonia, lung cancer risk underlies importance of vaccination against respiratory infections

    Link between viral pneumonia, lung cancer risk underlies importance of vaccination against respiratory infections

    New data add weight to the case for protecting against respiratory viruses as part of lung cancer prevention.